LUND, Sweden — /August 30, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has entered a customer agreement with WntResearch AB, a Swedish biopharma company advancing new anti-cancer therapies targeting the Wnt5A pathway. WntResearch is planning to launch a phase 2 trial in colorectal cancer patients of the drug candidate Foxy-5, for which SAGA’s ultrasensitive circulating tumor DNA analyses, KROMA™, will be employed to monitor patients’ tumor response.
“The agreement with SAGA Diagnostics is very important for WntResearch. The choice to use ctDNA as a proxy for recurrence of tumors in our trial was an early decision, but for us it was very important to find the best method. Our evaluation made us chose SAGA Diagnostics and the KROMA-technology for it’s measure of robust biomarkers with a very high sensitivity,” says Peter Morsing, CEO of WntResearch.
“The incorporation of circulating tumor DNA analysis to an oncology clinical trial promises to yield rich genomic information about every patient, quantitative data about tumor burden, and an earlier readout of response, together enabling faster and more efficient pharmaceutical development,” says SAGA CEO Lao Saal.
Contact: CEO Lao Saal, M.D. Ph.D. email@example.com Phone: +46 (0)70 – 888 52 61
About SAGA Diagnostics
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.